Related Experiment Videos
Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
M T Roe1, S K Sapp, A M Lincoff
1Division of Cardiology, Duke Clinical Research Institute, USA.
Cleveland Clinic Journal of Medicine
|February 19, 2000
Abstract:
Glycoprotein (GP) IIb/IIIa inhibitors are potent antiplatelet agents and represent an exciting breakthrough in the treatment of acute coronary syndromes. However, their safety and cost-effectiveness require further investigation, and more information on risk stratification is needed to clarify which patients benefit the most from empiric use of these agents.